Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT04778449
- Status
- Recruiting
Conditions
- Cutaneous Melanoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Medical Chart Review — OTHERMedical charts are reviewed
- Questionnaire Administration — OTHERComplete questionnaires
Study Details
This study investigates the extent to which lifestyle factors including mental health, social support, diet, and exercise are associated with quality of life and melanoma patient outcomes. Knowledge gained from this study may be used to guide the design of prospective clinical trials of lifestyle interventions to improve the outcomes of melanoma patients and assist doctors in counseling their patients.
Key Dates
- Start date
- Aug 26, 2015
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 5,000 participants (estimated)
Arms
- Arm: Observational (questionnaire, medical chart review)Patients complete a maximum of 3 paper or electronic questionnaires over 30 minutes within 2 weeks of presentation to MD Anderson, new diagnosis of melanoma, and/or initiating a new treatment, within 2 weeks of first restaging, and within 2 weeks of the end of treatment. Patients may complete an additional paper or electronic dietary questionnaire over 10 minutes for 3 days (30 minutes total) or a phone-based dietary recall. Patients who start a new treatment of interest may repeat the questionnaires at the same time points. Patients' medical records are also reviewed.
Primary Outcome Measure
Change in depression/distress [ Time Frame: Up to 10 years ]
Central Contacts
- Carrie Daniel-MacDougall713-563-5783
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | Carrie Daniel-MacDougall (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By research site
Related Studies
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsPHASE1/PHASE2 · Recruiting · IDEAYA Biosciences · Los Angeles, California
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationRecruiting · Guardant Health, Inc. · Birmingham, Alabama
- A Beta-only IL-2 ImmunoTherapY StudyPHASE1/PHASE2 · Recruiting · Medicenna Therapeutics, Inc. · San Diego, California
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerPHASE1/PHASE2 · Recruiting · Aulos Bioscience, Inc. · Miami, Florida